*Corresponding Author: Dr. Sarita Bhandari, Associate Professor, Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai - 600077, India. Email: saritabhandari.sdc@saveetha.com
Background: Matrix metalloproteinase (MMP) enzymes are endogenous proteolytic enzymes in dentin contributing to the dissolution of the collagen matrix. Hence, MMP inhibitors are being explored to enhance the longevity of restorations by reducing collagen degradation in secondary caries. This systematic review assesses the impact of MMP inhibitors used for pretreatment application in preventing secondary caries.
Methods: This systematic review was carried out following the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Three reviewers conducted the systematic literature search of five databases (Cochrane (CENTRAL), MEDLINE, Scopus, Science Direct and Web of Science) independently by 15 January 2025.
Results: After preliminary search, the titles and abstracts were screened, then 82 studies were identified for potential inclusion. After retrieving information related to objectives and outcome measures, the data was analyzed. After a thorough review, only two articles that adhered to the eligibility criteria were ultimately included for the analysis.
Conclusion: Pretreatment with MMP inhibitors did not significantly affect inhibition of secondary caries. However, the current evidence remains insufficient to establish a definitive correlation, necessitating further research.
Keywords: Dentin, Dental Caries, Outcome Assessment, Matrix Metalloproteinases.
How to cite this article: Khan HLA, Bhandari S, Uddin I. Relationship between matrix metalloproteinase inhibitors for dentin pre treatment and secondary caries inhibition at the tooth restoration interface - systematic review. Int J Drug Deliv Technol. 2026;16(3s): 772-780; DOI: 10.25258/ijddt.16.3s.94
Source of support: Nil.
Conflict of interest: None